MedTrace Logo

Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

NCT05672888 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-01-17

No results posted yet for this study

Summary

This was a randomized, double-blind, placebo-controlled parallel study.

Conditions

Interventions

DRUG

Jaktinib

100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.

DRUG

Placebo

Placebo (given as two placebo tablets) administered orally BID with best available treatment.

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Jianya Zhou · First Affiliated Hospital of Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2024-01-31
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05672888 on ClinicalTrials.gov